1242070-41-2

Upstream product

• 1242070-35-4 2-[2-(2,3-dimethoxyphenyl)-4-oxo-azetidin-3-yl]-4-nitroisoindole-1,3-dione 
• 93-11-8 2-Naphthalenesulfonyl chloride 

Relevant academic research and scientific papers

Petra, osiris, and molinspiration together as a guide in drug design: Predictions and correlation structure/antibacterial activity relationships of new N-sulfonyl monocyclic β-lactams

We report in this article the design and calculated molecular properties of 18 new mono-cyclic β-lactams 4-21, on the basis of one hypothetical antibacterial pharmacophore structure designed to interact with both of Gram-positive bacteria and Gram-negative bacteria. The in vitro biological evaluation of these compounds allowed us to point out new potential non-nucleoside hits, with MIC values in the range of 2-8 μg/mL active against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa. A correlation structure/antibacterial activities relationship of these monocyclic β-lactams is described. Supplemental materials are available for this article. Go to the publisher's online edition of Phosphorus, Sulfur, and Silicon and the Related Elements to view the free supplemental file.

Synthesis of new N-sulfonyl monocyclic β-lactams and the investigation of their antibacterial activities

New monocyclic β-lactams 4-6 were synthesized by a ketene-imine [2+2] cycloaddition reaction. The prepared monocyclic -lactams 4-6 were cleaved by ceric ammonium nitrate (CAN) to give NH β- lactams 7-9. The NH -β- lactams were converted to N-sulfonyl -lactams 10-21 by treatment with four different sulfonyl chlorides in the presence of Et3N and 4-N,N-dimethylaminopyridine (DMAP). Some of these monocyclic β-lactams were active against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa.